Low-temperature plasma treatment with atmospheric discharge with runaway electrons (DRE) was shown to be an efficient way to activate carbon fiber's (CF) surface and subsequently increase its interlayer shear strength (ILSS) values. It was demonstrated that an acceptable ILSS level was achieved after a DRE plasma treatment duration of 15 min. The treatment of CFs resulted in their surface roughness being increased and their functional groups grafting. The XPS data showed a change in the chemical composition and the formation of reactive oxygen-containing groups. SEM examinations of the PPS/CF laminates clearly demonstrated a difference in adhesive interaction at the PPS/CF interface. After the DRE plasma treatment, CFs were better wetted with the polymer, and the samples cohesively fractured predominantly through the matrix, but not along the PPS/CF interface, as was observed for the sample reinforced with the untreated CFs. The computer simulation results showed that raising the adhesive strength enhanced the ILSS values, but reduced resistance to transverse cracking under the loading pin. In general, higher flexural strength of the PPS/CF laminates was achieved with a greater interlayer adhesion level, which was consistent with the obtained experimental data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10780355 | PMC |
http://dx.doi.org/10.3390/polym16010121 | DOI Listing |
J Anim Sci Biotechnol
January 2025
College of Animal Science and Technology, Northeast Agricultural University, Harbin, 150030, People's Republic of China.
Background: The objective of this study was to evaluate the effects of dietary fatty acids (FA) saturation and lysophospholipids supplementation on growth, meat quality, oxidative stability, FA profiles, and lipid metabolism of finishing beef bulls. Thirty-two Angus bulls (initial body weight: 623 ± 22.6 kg; 21 ± 0.
View Article and Find Full Text PDFBMC Chem
January 2025
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nile Valley University (NVU), El Fayoum, 63518, Egypt.
Coronavirus disease 2019 (COVID-19), an extremely contagious illness, has posed enormous challenges to healthcare systems around the world. Although the evidence on COVID-19 management is growing, antiviral medication is still the first line of treatment. Therefore, it is critical that effective, safe, and tolerable antivirals be available to treat early COVID-19 and stop its progression.
View Article and Find Full Text PDFJ Transl Med
January 2025
Scientia Clinical Research and Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia.
Background: A novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC) GQ1001 was assessed in patients with previously treated HER2 positive advanced solid tumors in a global multi-center phase Ia dose escalation trial.
Methods: In this phase Ia trial, a modified 3 + 3 study design was adopted during dose escalation phase. Eligible patients were enrolled, and GQ1001 monotherapy was administered intravenously every 3 weeks.
BMC Vet Res
January 2025
Department of Animal Production, Faculty of Agriculture, Mansoura University, Mansoura, 35516, Egypt.
Phytochemicals have been effectively used to enhance the growth and productivity of farm animals, while the potential roles of essential oils and their nano-emulsions are limited. This plan was proposed to investigate the impacts of orally administered moringa oil (MO) or its nano-emulsion (NMO) on the growth, physiological response, blood health, semen attributes, and sperm antioxidant-related genes in rams. A total of 15 growing Rahmani rams were enrolled in this study and allotted into three groups.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!